BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $129.1250.

Several research analysts have weighed in on BNTX shares. Berenberg Bank cut their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the company from $117.00 to $135.00 in a research report on Wednesday, May 27th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Canaccord Genuity Group reduced their price target on shares of BioNTech from $171.00 to $158.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company decreased their price objective on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th.

Institutional Investors Weigh In On BioNTech

Large investors have recently modified their holdings of the stock. Larson Financial Group LLC grew its holdings in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the period. EFG International AG bought a new stake in shares of BioNTech in the fourth quarter valued at $29,000. Caitong International Asset Management Co. Ltd raised its stake in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the last quarter. Finally, Vestcor Inc purchased a new position in shares of BioNTech during the 4th quarter valued at $153,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 3.0%

NASDAQ:BNTX opened at $89.33 on Monday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The firm has a 50-day moving average price of $91.29 and a two-hundred day moving average price of $97.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The firm has a market cap of $22.59 billion, a price-to-earnings ratio of -15.19 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, May 4th. The company reported ($2.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.26. The firm had revenue of $136.71 million for the quarter, compared to the consensus estimate of $207.42 million. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The company’s revenue was down 35.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.73) EPS. On average, equities analysts expect that BioNTech will post -5.79 earnings per share for the current fiscal year.

BioNTech declared that its board has authorized a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.